![]() ![]() This decrease was (not significantly) higher, when 4 or less IVI were applied in the first yr (from 0.61 to 0.86 logMAR) as compared to >4 IVIs (from 0.64 to 0.68 logMAR). VA slightly decreased from 0.63 logMAR at baseline to 0.77 logMAR after 3 yrs of TX. of IVIs needed in the 2nd and 3rd yr could not be predicted from the IVI frequency in the 1st yr of TX. Comparing the group of patients with less than 5 IVI in the 1st year to those with >4 IVI, the no. Main outcome parameters were the VA change after a follow up (FU) of >3 yrs, the total number of IVI needed and the frequency of IVI in the 1st, 2nd and 3rd yr of TX.Ĩ8 eyes (88 patients, mean age 77.1 yrs, 55 females, 33 males) had a FU of >3yrs. Retrospective analysis of 88 patients with wet AMD, initially treated with either 3 IVI of bevacizumab (1.5mg) or ranibizumab (0.5mg), followed by PRN-IVI. The aim of this study is to investigate whether the IVI rate in the 1st yr can predict the IVI rate in the following years and whether a low IVI rate in the 1st yr is related to the same VA changes after 3yr as a higher IVI rate. ![]() ![]() However, a PRN-TX based on VA changes rather than OCT changes has less favourable results. In Germany, most insurance companies allowed a re-TX of active lesions only after at least 5 letters loss of visual acuity (VA) following the previous TX-course. MARINA, ANCHOR and HORIZON studies showed that visual acuity (VA) can be preserved by 4-weekly intravitreal injections (IVI) of ranibizumab over >2 years (yrs).In the CATT-trial ranibizumab and bevacizumab have comparable results on a monthly IVI treatment (TX) as well as on a PRN (pro re nata) TX. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |